Showing 2 posts of 2 posts found.
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
NEC joins €6.5m European project using AI for pandemic vaccine design
The evidence bar impacting UK medical cannabis access
Survey highlights mental health burden among rare disease patients and families
Addressing the rheumatic disease diagnostic gap in primary care
How chronic disease creates opportunity on diagnostic and therapeutic pipelines